Ratings BML, Inc.

Equities

4694

JP3799700004

Delayed Japan Exchange Other stock markets 02:00:00 2024-05-02 am EDT			5-day change	1st Jan Change
2,908 ^JPY	0.00%		+0.52%	-3.07%

May. 03	Boab Metals Raising AU$5 Million to Advance Sorby Hills Lead-Silver-Zinc Project; Shares Down 8%	MT
Mar. 22	Matsa Resources Receives More High-Grade Gold Assays from Devon Pit Mine in Western Australia; Shares Down 3%	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The company shows low valuation levels, with an enterprise value at 0.26 times its sales.
The company's share price in relation to its net book value makes it look relatively cheap.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last few months, analysts have been revising downwards their earnings forecast.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
BML, INC.	-3.07%	741M		-
SONIC HEALTHCARE LIMITED	-17.86%	8.3B		B+
SYNLAB AG	-8.58%	2.47B		-
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-38.71%	2.46B		B-
DR. LAL PATHLABS LIMITED	-9.32%	2.31B		B-
NEOGENOMICS, INC.	-5.44%	1.95B		C-
FLEURY S.A.	-17.79%	1.59B		A-
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.78%	1.21B		C+
METROPOLIS HEALTHCARE LIMITED	+6.69%	1.1B		B+
ADICON HOLDINGS LIMITED	-29.37%	931M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes